Daily Trades
- Dylan Jovine
Lots to discuss today, so I’m going to take them one at a time.
- Dylan Jovine
A lot of folks have written in to ask my if I think Recursion Pharmaceuticals (SYM: RXRX) is still a "BUY." Shares closed Friday at $11.93, a 39% gain from our recommended price of $8.57 a share.
- Dylan Jovine
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
Thanks to a new breakthrough… A new treatment for liver cancer was created in just 30 days.
- Dylan Jovine
Forbes Reports it: “Will save the lives of billions of people.” The BBC Reports: “It could spark a medical revolution.”
deal of the month
Categories
Dylan Jovine | 🚨 Treasury Secretary Warns of ‘Guaranteed’ Financial Crisis – What You Need to Know!
Dylan Jovine | The Market is Cracking — Here’s What Comes Next
Dylan Jovine | Market Volatility Alert: What History Tells Us About the Next 6 Months
Recent posts
Tags
Connect with Us
- Dylan Jovine
Lots to discuss today, so I’m going to take them one at a time.
- Dylan Jovine
A lot of folks have written in to ask my if I think Recursion Pharmaceuticals (SYM: RXRX) is still a "BUY." Shares closed Friday at $11.93, a 39% gain from our recommended price of $8.57 a share.
- Dylan Jovine
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
Thanks to a new breakthrough… A new treatment for liver cancer was created in just 30 days.
- Dylan Jovine
Forbes Reports it: “Will save the lives of billions of people.” The BBC Reports: “It could spark a medical revolution.”
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.